Upcoming catalysts in the second quarter of 2024 include US approval decisions on the vaccine V116 for the prevention of invasive pneumococcal disease and pneumococcal pneumonia, the small-molecule drug ensifentrine (RPL554) for chronic obstructive pulmonary disease (COPD) and the bispecific antibody tarlatamab for advanced small-cell lung cancer (SCLC).
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The author declares no competing interests.